BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Events calendar : University of Miami Miller School of Medicine - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Events calendar : University of Miami Miller School of Medicine
X-ORIGINAL-URL:https://events.med.miami.edu
X-WR-CALDESC:Events for Events calendar : University of Miami Miller School of Medicine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260605T080000
DTEND;TZID=America/New_York:20260605T090000
DTSTAMP:20260601T181155Z
CREATED:20260601T181155Z
LAST-MODIFIED:20260601T181155Z
UID:10003688-1780646400-1780650000@events.med.miami.edu
SUMMARY:Treatment Paradigm of Hepatocellular Carcinoma in 2026 | David Goldberg\, MD
DESCRIPTION:David Goldberg\, MD\nAssociate Professor of Medicine\nDivision of Digestive Health and Liver Diseases\nUniversity of Miami Miller School of Medicine \nDr. David Goldberg is an Associate Professor of Medicine in the Division of Digestive Health and Liver Diseases and Associate Professor of Public Health Sciences at the University of Miami Miller School of Medicine. Dr. Goldberg received his medical degree from the Mount Sinai School of Medicine\, followed by residency in internal medicine at New York Presbyterian Hospital-Columbia University Medical Center. He then completed fellowships in gastroenterology and then transplant hepatology at the University of Pennsylvania\, after which he was a faculty member from 2013-2019 before joining the faculty at the University of Miami Miller School of Medicine in 2019. \nJOIN HERE!\nDr. Goldberg’s objectives: \n\nIdentify the way HCC is staged.\nEvaluate treatment options for HCC based on stage.\nAnalyze the role of liver transplant for HCC.\n\nFaculty Disclosure\nDr. Goldberg has indicated he doesn’t have relevant financial relationships with ineligible companies. \nPlanning Committee Disclosure\nDr. Lekakis has indicated that he has no relevant financial relationships with commercial interests. \nTarget Audience\nFaculty\, Primary Care Physicians\, APRNs\, PharmD \nAccreditation\nThe University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. \nCredit Designation\nThe University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
URL:https://events.med.miami.edu/event/treatment-paradigm-of-hepatocellular-carcinoma-in-2026-david-goldberg-md/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
ATTACH;FMTTYPE=image/webp:https://events.med.miami.edu/wp-content/uploads/2026/06/image.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260529T080000
DTEND;TZID=America/New_York:20260529T090000
DTSTAMP:20260527T164511Z
CREATED:20260527T164118Z
LAST-MODIFIED:20260527T164511Z
UID:10003687-1780041600-1780045200@events.med.miami.edu
SUMMARY:The epigenetic-splicing synergism in the context of IDH2 and SRSF2 mutations in AML | Aristeidis Telonis\, PhD
DESCRIPTION:Aristeidis G. Telonis\, PhD\nResearch Assistant Professor\nBiochemistry and Molecular Biology\nUniversity of Miami  \nAristeidis G. Telonis\, PhD\, is a Research Assistant Professor in the Department of Biochemistry and Molecular Biology at the University of Miami Miller School of Medicine. His research combines computational biology\, genomics\, and systems-level approaches to study how retrotransposons and other repetitive elements shape gene regulation\, cellular identity\, and disease biology. His lab investigates how these genomic elements respond to environmental stress\, aging\, and therapy\, and how their dysregulation may contribute to cancer and other human diseases. Dr. Telonis’ work integrates high-throughput sequencing\, bioinformatics\, machine learning (AI)\, and molecular data analysis to uncover hidden layers of genome regulation with potential relevance to diagnosis\, prognosis\, and therapeutic response. \nJOIN HERE!\nDr. Telonis’ objectives: \n\nDescribe the expression\, epigenetic and splicing profiles characteristic of IDH2/SRSF2 mutations\nDescribe the relationship of the epigenome with RNA splicing\nExplain how the co-occurance of IDH2 and SRSF2 mutations increases leukemia aggressiveness\n\nFaculty Disclosure\nDr. Telonis has indicated he doesn’t have relevant financial relationships with ineligible companies. \nPlanning Committee Disclosure\nDr. Lekakis has indicated that he has no relevant financial relationships with commercial interests. \nTarget Audience\nFaculty\, Primary Care Physicians\, APRNs\, PharmD \nAccreditation\nThe University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. \nCredit Designation\nThe University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
URL:https://events.med.miami.edu/event/the-epigenetic-splicing-synergism-in-the-context-of-idh2-and-srsf2-mutations-in-aml-aristeidis-telonis-phd/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
ATTACH;FMTTYPE=image/jpeg:https://events.med.miami.edu/wp-content/uploads/2026/05/54413739-aristeidis-telonis.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260522T080000
DTEND;TZID=America/New_York:20260522T090000
DTSTAMP:20260520T161902Z
CREATED:20260520T161533Z
LAST-MODIFIED:20260520T161902Z
UID:10003682-1779436800-1779440400@events.med.miami.edu
SUMMARY:Expanding the Role of Hereditary Cancer Genetics in Academic Oncology Care | Nicholas A. Borja\, MD
DESCRIPTION:Nicholas A. Borja\, MD\nAssistant Professor of Clinical Genetics\nUniversity of Miami\, Miller School of Medicine  \nDr. Nicholas A. Borja is an Assistant Professor of Clinical Genetics in the Department of Human Genetics and a member of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine\, where he leads the High-Risk Genetics Program.  \nDr. Borja earned his bachelor’s degree from Williams College\, and his medical degree from the University of Pennsylvania School of Medicine. He pursued residency training in general surgery and a research fellowship in cancer biology at the University of Texas Southwestern\, followed by a medical genetics fellowship at the University of Miami/Jackson Health System. \nHis research focuses on hereditary cancer susceptibility\, and he is the principal investigator of the TRACE study\, which aims to identify novel genetic determinants of cancer risk and has received pilot funding from the American Cancer Society. He is also co-investigator for the NIH Undiagnosed Diseases Network Clinical Site of Miami\, where he characterizes ultra-rare genetic disorders and collaborates in gene discovery.  \nDr. Borja has authored studies that broaden the spectrum of phenotypes associated with Nevoid Basal Cell Carcinoma syndrome\, Coffin-Siris syndrome\, Sotos syndrome\, and ATM-related cancer susceptibility\, as well as research on the interplay of genetic and environmental factors in patients who have undergone solid organ transplantation and in those with multiple primary malignancies. \nJOIN HERE!\nDr. Borja’s objectives: \n• Recognize limitations of guideline-based germline testing and identify clinical scenarios in which hereditary cancer susceptibility may be missed.\n• Explain new practices for identifying cancer susceptibility and how this may impact treatment selection\, early detection of cancer\, cascade testing\, and family risk assessment\n• Describe how genome sequencing\, tumor–germline integration\, and emerging technologies can improve diagnostic yield\, provide mechanistic insights\, and enable gene discovery in high-risk cancer patients \nFaculty Disclosure\nDr. Borja has indicated she doesn’t have relevant financial relationships with ineligible companies. \nPlanning Committee Disclosure\nDr. Lekakis has indicated that he has no relevant financial relationships with commercial interests. \nTarget Audience\nFaculty\, Primary Care Physicians\, APRNs\, PharmD \nAccreditation\nThe University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. \nCredit Designation\nThe University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
URL:https://events.med.miami.edu/event/expanding-the-role-of-hereditary-cancer-genetics-in-academic-oncology-care-nicholas-a-borja-md/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
ATTACH;FMTTYPE=image/png:https://events.med.miami.edu/wp-content/uploads/2026/05/Nicholas-A-Borja-headshot-e1779293791285.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260515T080000
DTEND;TZID=America/New_York:20260515T090000
DTSTAMP:20260514T202416Z
CREATED:20260514T202257Z
LAST-MODIFIED:20260514T202416Z
UID:10003680-1778832000-1778835600@events.med.miami.edu
SUMMARY:Optimal Management of Localized Pancreatic Adenocarcinoma- A Surgeon's Approach | Caitlin Hester\, MD
DESCRIPTION:Caitlin Hester\, MD\nAssistant Professor of Surgery\nUniversity of Miami \nDr. Caitlin Hester is a board-certified surgeon and specializes in minimally invasive and open operations for gastrointestinal malignancies with a focus on cancers of the liver\, pancreas\, bile duct\, and stomach.  She obtained her medical degree from Medical College of Georgia.  She completed seven years of general surgery training at the University of Texas Southwestern and a two-year Complex General Surgical Oncology fellowship at MD Anderson Cancer Center. \nHer clinical research aimed at studying the genotypic and phenotypic profiles of pancreatic tumors and mechanisms that may contribute to treatment sensitivity. She plans to integrate response to therapy into clinical trial design in hopes of individualizing treatment plans for patients. \nShe has served as the Quality Improvement Fellow Officer at MD Anderson Cancer Center and as a representative on the Diversity\, Equity\, and Inclusion Committee for the Department of Surgery at UT Southwestern Medical Center.  She is passionate about DEI work and has dedicated a significant amount of time to community service efforts directed toward improving educational opportunities and early exposure to the field of medicine for underrepresented minorities. \nShe was awarded the Gary Purdue Chief Resident of the Year Award at the University of Texas Southwestern for exemplifying clinical excellence and dedication to patient care.\nIt is her greatest privilege to care for patients with cancer\, and it is her mission to provide every opportunity to improve quality of life and longevity for her patients. \nJOIN HERE!\nDr. Hester’s objectives: \n• Distinguish resectable\, borderline resectable\, and locally advanced PDAC\n• Analyze the ideal duration and sequence of chemotherapy for resectable\, borderline resectable\, and locally advanced PDAC\n• Be able to describe the treatment arms and outcomes of the following trials: PRODIGE 24\, SWOG S1505\, Alliance A201501\, and CASSANDRA \nFaculty Disclosure\nDr. Hester has indicated she doesn’t have relevant financial relationships with ineligible companies. \nPlanning Committee Disclosure\nDr. Lekakis has indicated that he has no relevant financial relationships with commercial interests. \nTarget Audience\nFaculty\, Primary Care Physicians\, APRNs\, PharmD \nAccreditation\nThe University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. \nCredit Designation\nThe University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
URL:https://events.med.miami.edu/event/optimal-management-of-localized-pancreatic-adenocarcinoma-a-surgeons-approach-caitlin-hester-md/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
ATTACH;FMTTYPE=image/jpeg:https://events.med.miami.edu/wp-content/uploads/2026/05/Headshot-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260410T080000
DTEND;TZID=America/New_York:20260410T090000
DTSTAMP:20260408T161607Z
CREATED:20260408T161607Z
LAST-MODIFIED:20260408T161607Z
UID:10003641-1775808000-1775811600@events.med.miami.edu
SUMMARY:CXCL9: A Marker of Impending Doom in Adult Hyperinflammation | Joseph Hai Oved\, MD
DESCRIPTION:Joseph Hai Oved\, MD\nThe Kennedy Family Associate Professor of Pediatrics (in Medicine)\nDirector\, Program in Immune Dysregulation\nPediatric Transplantation & Cellular Therapies\nColumbia University / Irving Medical Center \nJOIN HERE!\nDr. Lombard’s objectives: \n\nKnow that CXCL9 is an important marker of IFNg activation.\nIdentify when to conduct a hyperinflammatory workup in a critically ill patient.\nEvaluate which patients may benefit from early immune modulation\n\nFaculty Disclosure\nDr. Oved has indicated that he has the following relevant financial relationships with ineligible companies: \nAdvisor – Sobi \nPlanning Committee Disclosure\nDr. Lekakis has indicated that he has no relevant financial relationships with commercial interests. \nTarget Audience\nFaculty\, Primary Care Physicians\, APRNs\, PharmD \nAccreditation\nThe University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. \nCredit Designation\nThe University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
URL:https://events.med.miami.edu/event/cxcl9-a-marker-of-impending-doom-in-adult-hyperinflammation-joseph-hai-oved-md/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
ATTACH;FMTTYPE=image/jpeg:https://events.med.miami.edu/wp-content/uploads/2026/04/Headshot-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260130T080000
DTEND;TZID=America/New_York:20260130T090000
DTSTAMP:20260122T214831Z
CREATED:20260120T230215Z
LAST-MODIFIED:20260122T214831Z
UID:10003471-1769760000-1769763600@events.med.miami.edu
SUMMARY:Hematopoietic Cell Transplantation - Then and Now | Frederick R. Appelbaum\, MD
DESCRIPTION:📅 Friday\, January 30\, 2026\n🕐 8:00 AM – 9:00 AM\n📍 Hybrid Event\n Location: Sylvester Cancer Center\, Room 1301\nJoin Zoom\n\n \n\nHematology / Medical Oncology Grand Rounds \n“Hematopoietic Cell Transplantation – Then and Now” \n\n \n\n \n\nFrederick R. Appelbaum\, MD\nExecutive Vice President \nFred Hutchinson Cancer Center \nProfessor of Medicine \nUniversity of Washington \n\n\n \n\nAbout Dr. Appelbaum\nFrederick R. Appelbaum\, M.D.\, is Executive Vice President of the Fred Hutchinson Cancer Center.  He is a diplomat on the American Boards of Internal Medicine and Medical Oncology\, is past chair of the Board of Scientific Advisors of the National Cancer Institute and is a member of the National Academy of Medicine.  Additionally\, he has served on the boards of numerous scientific societies\, including the American Society of Hematology\, American Society of Clinical Oncology\, American Association for Cancer Research\, and the American Society for Blood and Marrow Transplantation. \nDr. Appelbaum is Head of the Hematologic Malignancies Program at the Fred Hutch/University of Washington Cancer Consortium and is the author of over 900 scientific articles. He was the lead author on the first paper to describe the successful use of autologous marrow transplantation\, and was co-inventor of gemtuzumab ozogamicin\, the first antibody-drug conjugate ever approved by the FDA. \nDr. Appelbaum’s current areas of research center on the biology and treatment of hematologic malignancies. He is the author of the recent book Living Medicine: Don Thomas\, Marrow Transplantation\, and the Cell Therapy Revolution. \n\n \n\nLearning Objectives\nAt the conclusion of this activity\, participants will be able to: \n\n\nAnalyze the key steps allowing the development of allogeneic HCT \n\n\nIdentify character traits of Don Thomas contributing to his success \n\n\nDefine major areas of current research in HCT \n\n\n\n \n\nTarget Audience: Faculty\, Primary Care Physicians\, APRNs\, PharmD\, Fellows \n\n \n\nVenue\n\nHybrid Event – In person attendance is encouraged \nLocation: Sylvester Cancer Center\, Room 1301 \nJoin via Zoom \nJoin Zoom \n\n\n \n\nDisclosures\n\nCommercial Interests \nDr. Appelbaum has indicated he doesn’t have relevant financial relationships with ineligible companies. \n\n\n \n\nEvent Category\nDept. of Medicine · Hematology · Medical Oncology · Grand Rounds \n\n \n\nHematology / Medical Oncology Grand Rounds \n“Hematopoietic Cell Transplantation – Then and Now” \nFriday\, January 30\, 2026 · 8:00 AM – 9:00 AM · Hybrid Event \nJoin Zoom
URL:https://events.med.miami.edu/event/hematopoietic-cell-transplantation-then-and-now-frederick-r-appelbaum-md-hybrid-event/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260123T080000
DTEND;TZID=America/New_York:20260123T090000
DTSTAMP:20260122T183714Z
CREATED:20260121T155456Z
LAST-MODIFIED:20260122T183714Z
UID:10003472-1769155200-1769158800@events.med.miami.edu
SUMMARY:Brain Metastases in Melanoma in the Clinic\, in the Lab\, and in the Future | Kim Margolin\, MD\, FASCO
DESCRIPTION:📅 Friday\, January 23\, 2026\n🕐 8:00 AM – 9:00 AM\n📍 Hybrid Event\n Location: Sylvester Cancer Center\, Room 1301\nJoin Zoom\n\n \n\nHematology / Medical Oncology Grand Rounds \n“Brain Metastases in Melanoma – in the Clinic\, in the Lab\, and in the Future” \n\n \n\n \n\nKim Margolin\, MD\, FASCO\nMedical Director \nMelanoma Program \nSt. John’s Cancer Institute \n\n\n \n\nAbout Dr. Margolin\n  \n\n \n\nLearning Objectives\nAt the conclusion of this activity\, participants will be able to: \n\n\nRecognize the probability of brain metastasis development in melanoma \n\n\nIdentify factors that increase the risk of brain metastasis in melanoma \n\n\nSelect the optimal therapy for patients with melanoma and brain metastasis \n\n\n\n \n\nTarget Audience: Faculty\, Primary Care Physicians\, APRNs\, PharmD\, Fellows \n\n \n\nVenue\n\nHybrid Event – In person attendance is encouraged \nLocation: Sylvester Cancer Center\, Room 1301 \nJoin via Zoom \nJoin Zoom \n\n\n \n\nDisclosures\n\nCommercial Interests \nDr. Margolin has the following relevant financial relationships with ineligible companies: \nGrant or research support | Regeneron Pharmaceuticals\, Inc.\, Immunocore\, Agenus\, Merck \nAdvisor | Ovance\, Elicio \nAdvisory Committees | Beigene\, AstraZeneca\, Bristol-Myers Squibb Company\, Daiichi Sankyo\, Inc \n\n\n \n\nEvent Category\nDept. of Medicine · Hematology · Medical Oncology · Grand Rounds \n\n \n\nHematology / Medical Oncology Grand Rounds \n“Brain Metastases in Melanoma – in the Clinic\, in the Lab\, and in the Future“ \nFriday\, January 23\, 2026 · 8:00 AM – 9:00 AM · Hybrid Event \nJoin Zoom
URL:https://events.med.miami.edu/event/brain-metastases-in-melanoma-in-the-clinic-in-the-lab-and-in-the-future-kim-margolin-md-fasco/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251203T130000
DTEND;TZID=America/New_York:20251203T140000
DTSTAMP:20251126T140153Z
CREATED:20251126T135716Z
LAST-MODIFIED:20251126T140153Z
UID:10003357-1764766800-1764770400@events.med.miami.edu
SUMMARY:Cancer Control and Cancer Metabolism Seminar Series
DESCRIPTION:“Metabolism-Targeted Interventions for Improving Cancer Outcomes”\nLunch Served!\nJoin Zoom \n\nGuest Speaker:\n \n  \n  \nDorothy Sears\, PhD\nProfessor of Nutrition\nExecutive Director of Clinical and Community Translational\nScience in the College of Health Solutions\nCo-Lead of the Cancer Prevention & Control Translational Team\nArizona State University \n\n\n  \n\nWhen:\nWednesday\, December 3\, 2025\n1:00 pm – 2:00 pm \n\nWhere:\nSCCC 1301 \n\nTopic:\n“Metabolism-Targeted Interventions for Improving Cancer Outcomes” \n\nAbout:\nDr. Sears obtained her PhD training in Molecular Biology & Genetics at The Johns Hopkins University School of Medicine and completed fellowship training in the Division of Endocrinology & Metabolism at UC San Diego. She was a member of the UCSD School of Medicine faculty for 21 years. She has been conducting obesity-related cardiometabolic disease and cancer research since 1995 using cellular and animal models and clinical studies. She has been continuously funded by NIH since 2006. Her on-going transdisciplinary scope of research spans the molecular to population health levels.Dr. Sears studies health-promoting behaviors and the molecular mechanisms that underly these. Her most active areas of translational research are focused on the health benefits of aligning food intake with circadian rhythms and reducing prolonged sitting time.
URL:https://events.med.miami.edu/event/cancer-control-and-cancer-metabolism-seminar-series/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Molecular and Cellular Pharmacology
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250418T080000
DTEND;TZID=America/New_York:20250418T090000
DTSTAMP:20250418T122409Z
CREATED:20250415T143948Z
LAST-MODIFIED:20250418T122409Z
UID:10003043-1744963200-1744966800@events.med.miami.edu
SUMMARY:Development in CAR-T Cells in Brazil - Challenges and Opportunities | Renato Cunha\, MD\, PhD (HYBRID)
DESCRIPTION:Renato Cunha\, MD\, PhD\nProfessor\nPaulista Medical School\,\nFederal University of São Paulo \nDr. Cunha began his medical journey with a degree from the Faculty of Medicine at the Federal University of Uberlândia\, where he also completed a residency in internal medicine. He went on to specialize through a clinical fellowship in hematology\, bone marrow transplantation\, and cell therapy at the University of São Paulo. Dr. Dr. Cunha further advanced his academic training by pursuing a joint Ph.D. in cell therapy and biotechnology at both the University of São Paulo (Brazil) and the University of Paris-Diderot (France). In 2018\, he was awarded a prestigious postdoctoral fellowship at the National Cancer Institute in the United States. In 2019\, Dr. Cunha performed the first academic CAR T-cell treatment in Latin America and later played a key role in coordinating the first Brazilian Consensus on Advanced Cellular Therapy in 2021. \nIn Person: Sylvester Conference Room 1301 \nJOIN HERE!\nDr. Cunha’s objectives: \n\nAnalyze the principles and challenges to establish an advanced cell therapy manufacturing platform\nAnalyze the challenges of developing advanced cell therapy in low- to middle-income countries\nAnalyze the principles of development of advanced cell therapy from the bench to bedside\n\nFACULTY DISCLOSURE: \nDr. Cunha has indicated that he has no relevant financial relationships with commercial interests. \nPlanning Committee Disclosure\nDr. Lekakis has indicated that he has no relevant financial relationships with commercial interests. \nTarget Audience\nFaculty\, Primary Care Physicians\, APRNs\, PharmD \nAccreditation\nThe University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. \nCredit Designation\nThe University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
URL:https://events.med.miami.edu/event/development-in-car-t-cells-in-brazil-challenges-and-opportunities-renato-cunha-md-phd-hybrid/
LOCATION:Sylvester Conference Room 1301
CATEGORIES:Dept. of Medicine,Hematology,Medical Oncology,Pediatrics
ATTACH;FMTTYPE=image/png:https://events.med.miami.edu/wp-content/uploads/2025/04/5-HeadshotPicture-RCunha-e1744727716599.png
END:VEVENT
END:VCALENDAR